Wang Shuyi, Zheng Gang, Chen Liangdong, Xiong Bin
Department of Oncology, Zhongnan Hospital of Wuhan University, Wuhan, China.
Asian Pac J Cancer Prev. 2011;12(6):1417-23.
Her-2/neu is the most frequently studied molecular target in gastric cancer but its prognostic impact is still equivocal. We therefore conducted a meta-analysis to more precisely estimate its prognostic significance.
Published studies that investigated between Her-2/neu status and survival were identified. Meta-analysis was performed by Dersimonian-Laird model. Pooled hazard ratio (HR) and its 95% confidence interval (95%CI) were calculated to evaluate the risk of disease.
A total of 19 studies were analyzed by meta-analysis method, cumulative 4342 cases were included. Pooled data of 15 studies using univariate analysis showed worse survival of patient with her-2/neu (+) (pooled HR=1.59, 95%CI: 1.20-2.12), which maintained in 7 studies of multivariate analysis (pooled HR=1.58, 95%CI: 1.18-2.12). The Q statistic test for 15 studies of univariate analysis and for 7 studies of multivariate analysis showed they had heterogeneity (Q=26.98, p=0.019, Q=17.76, p=0.007, respectively).
HER-2/neu over-expression is related to poor prognosis of gastric cancer but has a modest effect on survival in gastric cancer as an independent prognosis factor.
Her-2/neu是胃癌中研究最频繁的分子靶点，但其预后影响仍不明确。因此，我们进行了一项荟萃分析，以更精确地评估其预后意义。
确定了研究Her-2/neu状态与生存之间关系的已发表研究。采用Dersimonian-Laird模型进行荟萃分析。计算合并风险比（HR）及其95%置信区间（95%CI），以评估疾病风险。
通过荟萃分析方法共分析了19项研究，纳入累计4342例病例。15项研究的单因素分析汇总数据显示，Her-2/neu（+）患者的生存率较差（合并HR=1.59，95%CI：1.20-2.12），在7项多因素分析研究中这一结果依然存在（合并HR=1.58，95%CI：1.18-2.12）。15项单因素分析研究和7项多因素分析研究的Q统计检验显示它们存在异质性（Q分别为26.98，p=0.019；Q为17.76，p=0.007）。
HER-2/neu过表达与胃癌预后不良相关，但作为独立预后因素对胃癌生存的影响较小。
